A Randomized, Double-Blind, Phase 4 Study to Evaluate the Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation
Phase of Trial: Phase II
Latest Information Update: 17 May 2017
Price : $35 *
At a glance
- Drugs Dexlansoprazole (Primary)
- Indications Metaplasia
- Focus Therapeutic Use
- Sponsors Takeda
- 23 Aug 2016 Status changed from active, no longer recruiting to discontinued.
- 06 Apr 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 17 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.